Thermo Fisher Scientific Trading Volume Drops 28.99% Ranking 96th in Market Activity

On May 28, 2025, Thermo Fisher Scientific (TMO) experienced a significant decline, with its trading volume dropping by 28.99% to 7.77 billion, ranking 96th in the day's market activity. The stock price decreased by 0.35%.

Thermo Fisher Scientific is set to highlight its advancements in precision oncology at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will showcase its integrated solutions, from biomarker discovery to commercialization, through poster presentations, abstracts, and booth demos. This year marks a decade of partnership with pharmaceutical companies in developing and commercializing NGS companion diagnostics, supporting new drug launches globally with decentralized in-country solutions.

Thermo Fisher's commitment to clinical research is evident in its support for over 750 hematology and oncology clinical trials, involving more than 175,000 patients across 35,000 sites in over 100 countries. The company's patient-centered approach to trial design and execution ensures that studies are both scientifically rigorous and accessible.

Kathy Davy, president of Clinical Next-Generation Sequencing at Thermo Fisher Scientific, emphasized the company's dedication to equipping clinicians with fast, reliable insights for timely treatment decisions. Davy will deliver opening remarks at the Canadian Evening at ASCO 2025, celebrating progress in cancer research.

At ASCO 2025, Thermo Fisher and its customers will present new data on precision oncology, including evaluations of decentralized NGS assays for identifying HRD and BRCA mutations in ovarian cancer, and the association between targeted therapy and survival in patients with AML. Attendees can connect with Thermo Fisher experts to learn more about the company's support for oncology programs from research through commercialization.